Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV, single center pilot study using alemtuzumab (Campath-1H) induction combined with prednisone-free, calcineurin-inhibitor-free immunosuppression in kidney transplantation

Next Previous
Search
Trial Profile

A phase IV, single center pilot study using alemtuzumab (Campath-1H) induction combined with prednisone-free, calcineurin-inhibitor-free immunosuppression in kidney transplantation

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Mycophenolate mofetil; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms Cell220

Most Recent Events

  • 23 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 04 May 2011 Five-year results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
  • 12 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top